An open-label phase I study to investigate the drug-drug interaction between GR-MD-02 and midazolam
Phase of Trial: Phase I
Latest Information Update: 18 May 2015
At a glance
- Drugs GR MD 02 (Primary) ; Midazolam
- Indications Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- 18 May 2015 New trial record
- 14 May 2015 According to a Galectin Therapeutics media release, this study was required by the US FDA. The lack of a drug interaction in this study will permit Galectin to expand the number of patients eligible for its Phase 2 clinical trial.
- 14 May 2015 Results published in a Galectin Therapeutics media release.